The chemical class of CCK-AR activators is primarily composed of compounds that influence the cholecystokinin receptor type A indirectly through the modulation of intracellular signaling pathways, particularly those involving cyclic AMP (cAMP). This class predominantly includes phosphodiesterase (PDE) inhibitors, such as IBMX, caffeine, theophylline, and various specific inhibitors like rolipram, zaprinast, sildenafil, vardenafil, tadalafil, milrinone, amrinone, and cilostazol. These compounds function by inhibiting the breakdown of cAMP, thereby increasing its intracellular concentration. Elevated levels of cAMP are known to potentiate GPCR pathways, which can lead to enhanced activation of receptors like CCK-AR.
The role of PDE inhibitors in this class highlights the importance of cAMP as a secondary messenger in cellular signaling. By preventing the degradation of cAMP, these compounds facilitate the amplification of signaling cascades that are essential for various physiological responses. In the context of CCK-AR, increased cAMP levels can lead to a more robust activation of the receptor's signaling pathway, which is critical for its physiological functions, including roles in digestion and satiety. Forskolin, another significant member of this class, directly stimulates adenylyl cyclase, leading to increased cAMP production. This mechanism further underscores the central role of cAMP modulation in the indirect activation of CCK-AR. The actions of these compounds reflect a strategic approach to influencing receptor activity by targeting upstream elements of the signaling pathway, thereby providing a broader and more versatile means of modulating receptor function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Increases cAMP levels; might enhance CCK-AR signaling by potentiating G-protein-coupled receptor (GPCR) pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-specific phosphodiesterase inhibitor; could increase cAMP, potentially enhancing CCK-AR-mediated signaling. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
A phosphodiesterase inhibitor; might indirectly increase CCK-AR activity by elevating intracellular cAMP levels. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Another phosphodiesterase inhibitor; could enhance CCK-AR signaling by increasing cAMP. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Inhibits phosphodiesterase 4; might boost CCK-AR function by raising cAMP levels. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
A phosphodiesterase 5 inhibitor; could potentially enhance CCK-AR signaling through increased cAMP. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
A PDE5 inhibitor; could enhance CCK-AR activity by increasing cAMP in relevant pathways. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Another PDE5 inhibitor; might indirectly stimulate CCK-AR signaling through elevated cAMP. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Inhibits phosphodiesterase 3; could increase cAMP levels, potentially enhancing CCK-AR activity. | ||||||
Amrinone | 60719-84-8 | sc-207288 | 1 g | $193.00 | ||
A phosphodiesterase 3 inhibitor; might boost CCK-AR function by raising cAMP levels. | ||||||